Venn Life Sciences Holdings PLC Contract wins (0537G)
03 August 2016 - 4:00PM
UK Regulatory
TIDMVENN
RNS Number : 0537G
Venn Life Sciences Holdings PLC
03 August 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Contract wins
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation (CRO) providing drug development, clinical trial
management and resourcing solutions to pharmaceutical,
biotechnology and medical device clients, announces that it has
signed a new contract worth EUR2.8m with a European Biotechnology
client. The clinical trial is a Phase II study in the area of
Immunotherapeutic treatments for Multiple Sclerosis and involves
patients in six countries across Europe and commences in October
2016.
Furthermore Venn's Interactive Response Technology ("IRT")
department, which centralises the randomisation of patients for
Phase I to IV clinical trails and manages the logistics of these
studies, has successfully qualified as a service provider to a top
ten Pharmaceutical client and has been awarded an initial project
involving thirty sites in China. This vendor qualification is a
significant milestone for the IRT division and represents an
exciting opportunity to grow a global account.
Commenting, Venn CEO, Tony Richardson said: "I am pleased to see
the addition of a significant new account for Venn. We are now
benefitting from a good balance of repeat business, client referals
and new business wins from prospecting. I am particularly pleased
with our success in IRT. Coming through the vendor qualification
and audit process with "big-pharma" represents a significant step
for our organisation and high quality execution of this initial
project should result in a rich vein of new business."
Enquiries:
Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Jonathan Hartshorn, Chief Financial Officer Tel: +353 153 93 269
Aoife O Farrell, Marketing Manager Tel: +353 153 93 269
Davy (Nominated Adviser, ESM Adviser Tel: +353 1 679 6363
and Joint Broker)
Fergal Meegan / Matthew DeVere White
(Corporate Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint-Broker)
Claire Louise Noyce Tel: 020 3764 2341
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a
Contract Research Organisation providing drug development, clinical
trial management and resourcing solutions to pharmaceutical,
biotechnology and medical device organisations. With dedicated
operations in France, Germany, the Netherlands, the UK, Ireland and
Europe wide representation - Venn Life Sciences specialises in
rapid deployment and management of multisite projects, across all
phases. Venn Life Sciences also has an innovation division -
Innovenn - focused primarily on breakthrough development
opportunities in Skin Science.
For more information about the Company, please visit:
www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUURBRNSAWRAR
(END) Dow Jones Newswires
August 03, 2016 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024